A Phase 1, Open-Label, Dose-Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Multiple Intravenous Doses of IGN002 Administered Weekly to Subjects with Refractory Non-Hodgkin Lymphoma

被引：0
|
作者：
Young, Patricia A.
Mataveli, Fabio D.
机构：
来源：
BLOOD | 2020年 / 136卷
关键词：
D O I：
10.1182/blood-2020-137784
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：3
相关论文
共 50 条
  • [21] Interim analysis of a phase 1, open-label, dose-escalation study of SGN-CD19A in patients with relapsed or refractory B-lineage non-Hodgkin lymphoma (NHL).
    Forero-Torres, Andres
    Moskowitz, Craig
    Advani, Ranjana H.
    Shah, Bijal D.
    Kostic, Ana
    Albertson, Tina M.
    Sandalic, Larissa
    Zhao, Baiteng
    Fanale, Michelle A.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [22] Antibody-interferon-alpha fusion protein (IGN002) for the treatment of b-cell non-Hodgkin lymphomas: A phase 1, first-in-human, dose-escalation trial
    Young, Patricia Ann
    Dang, Nam H.
    Nastoupil, Loretta J.
    Minning, Dena
    Gresser, Michael J.
    Timmerman, John
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [23] A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY AND TOLERABILITY STUDY OF NC762 IN SUBJECTS WITH ADVANCED OR METASTATIC SOLID TUMORS
    Myint, Han
    Shah, Satish
    Gutierrez, Martin
    Zsiros, Emese
    Nelson, Megan
    Zeidan, Stephanie
    Myrthil, Nadia
    Morawski, Aaron
    Barbu, Alina
    Shaik, Jahangheer
    Zhou, Chelsea
    Kanellopoulou, Chrysi
    Copeland, Ron
    Cusumano, Zachary
    Flies, Dallas
    Langermann, Solomon
    Lorusso, Patricia
    Odunsi, Kunle
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 : A781 - A781
  • [24] A phase I, open-label, dose-escalation study to evaluate the safety, tolerability, pharmacokinetics, and antitumor activity of ADCT-601 in patients with advanced solid tumours
    Tolcher, A. W.
    Falchook, G.
    Bendell, J. C.
    Ungar, D.
    Boni, J.
    Chao, G.
    Patel, M. R.
    ANNALS OF ONCOLOGY, 2019, 30 : 176 - +
  • [25] Weekly bortezomib in combination with temsirolimus in relapsed or relapsed and refractory multiple myeloma: a multicentre, phase 1/2, open-label, dose-escalation study
    Ghobrial, Irene M.
    Weller, Edie
    Vij, Ravi
    Munshi, Nikhil C.
    Banwait, Ranjit
    Bagshaw, Meghan
    Schlossman, Robert
    Leduc, Renee
    Chuma, Stacey
    Kunsman, Janet
    Laubach, Jacob
    Jakubowiak, Andrzej J.
    Maiso, Patricia
    Roccaro, Aldo
    Armand, Philippe
    Dollard, Akari
    Warren, Diane
    Harris, Brianna
    Poon, Tiffany
    Sam, Amy
    Rodig, Scott
    Anderson, Kenneth C.
    Richardson, Paul G.
    LANCET ONCOLOGY, 2011, 12 (03): : 263 - 272
  • [26] Phase 1 Dose-Escalation Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Tofacitinib in Japanese Healthy Volunteers
    Miyoshi, So
    Krishnaswami, Sriram
    Toyoizumi, Shigeyuki
    Nakamura, Hiroyuki
    Zwillich, Samuel H.
    CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT, 2020, 9 (01): : 11 - 20
  • [27] Phase 1b/2a Open-Label, Multiple-Dose, Dose-Escalation Study To Evaluate The Safety and Tolerability Of Intravenous Infusion Of SNS01-T In Patients With Relapsed Or Refractory Multiple Myeloma, Mantle Cell Lymphoma, Or Diffuse Large B Cell Lymphoma
    Lust, John A.
    Barranco, Charles
    Usmani, Saad Z.
    van Rhee, Frits
    Hamadani, Mehdi
    Thompson, John
    Taylor, Catherine A.
    Dondero, Richard
    Browne, Leslie J.
    Siegel, David
    Bensinger, William I.
    BLOOD, 2013, 122 (21)
  • [28] An open-label, exploratory, limited dose escalation study to evaluate the pharmacokinetics, safety and tolerability of gemcitabine hydrochloride oral formulation in subjects with malignant tumors
    Gabrail, Nashat Y.
    Ghamande, Sharad A.
    Silverman, Michael H.
    Smith, Carrie L.
    Ho, Hsiang-Ling
    Huang, Chia-Tsung
    Hsueh, Shu-Ping
    Lin, Chia-Li
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [29] Camidanlumab tesirine in patients with relapsed or refractory lymphoma: a phase 1, open-label, multicentre, dose-escalation, dose-expansion study
    Hamadani, Mehdi
    Collins, Graham P.
    Caimi, Paolo F.
    Samaniego, Felipe
    Spira, Alexander
    Davies, Andrew
    Radford, John
    Menne, Tobias
    Karnad, Anand
    Zain, Jasmine M.
    Fields, Paul
    Havenith, Karin
    Cruz, Hans G.
    He, Shui
    Boni, Joseph
    Feingold, Jay
    Wuerthner, Jens
    Horwitz, Steven
    LANCET HAEMATOLOGY, 2021, 8 (06): : E433 - E445
  • [30] Phase I, Open-Label, Dose-Escalation Study of the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of GSK2879552 in Relapsed/Refractory SCLC
    Bauer, Todd M.
    Besse, Benjamin
    Martinez-Marti, Alex
    Trigo, Jose Manuel
    Moreno, Victor
    Garrido, Pilar
    Ferron-Brady, Geraldine
    Wu, Yuehui
    Park, Jennifer
    Collingwood, Therese
    Kruger, Ryan G.
    Mohammad, Helai P.
    Ballas, Marc S.
    Dhar, Arindam
    Govindan, Ramaswamy
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : 1828 - 1838
12345